


FY2025 Financial Results

Profit and Loss Recognition Period for Deciphera Pharmaceuticals, Inc.



Regarding the profit and loss recognition for Deciphera Pharmaceuticals, Inc., nine months were recorded in the same period last year, while twelve months have been recorded this year.



Main Points of the Financial Results

Achieved revenue and profit growth and record-highest earnings ever.

Full-Year Result (FY2025)

FY2025: Record-High Revenue and Profit with Strong Year-on-Year Growth

Revenue increased to 515.8 JPY bn (+5.9% YoY), driven by strong growth in overseas products, reaching a record high. Core operating profit increased to 137.1 JPY bn (+21.7% YoY), supported by improved cost efficiency. Core profit attributable to owners of the Company reached 103.5 JPY bn (+14.5% YoY), the highest level since the introduction of core indicators.*

Full-Year Forecast (FY2026)

FY2026 Outlook: Lower Revenue and Profit with Continued R&D Investment

Revenue is expected to be 455.0 JPY bn (-11.8% YoY), mainly due to the termination of the co-promotion agreement with AstraZeneca for Forxiga. The Company plans to continue investing in research and development at approximately 30% of net sales, in order to advance global clinical trials aimed at expanding its pipeline. Therefore, core operating profit is expected to be 124.0 JPY bn (-9.6% YoY).

Research & Development

- Tirabrutinib is under FDA review following NDA acceptance.
- Sapablursen has entered a global Phase 3 trial.
- Phase 2 data for ONO-4578 and ONO-2808 are expected to be presented at scientific meetings.
- Four new pipelines have advanced into Phase 1 trials.

FY2025 : Sales Revenue



Revenue

515.8 JPY bn

YoY +28.9 JPY bn
(+5.9%)



Goods and Products Sales

342.6 JPY bn

YoY +11.8 JPY bn (+3.6%)




Royalty and Others

173.2 JPY bn

YoY +17.1 JPY bn (+10.9%)

FY2025 : Sales Revenue (Breakdown)

Although sales of OPDIVO decreased due to intensified competitive environment, overall sales increased by 28.9 JPY bn year on year, mainly due to higher royalty revenue associated with OPDIVO and other products and revenue from Deciphera.



FY2025 : Sales Revenue by Product / Japan

JPY bn	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
Revenue	486.9	<u>515.8</u>	28.9	5.9%	490.0
Goods and products	330.8	<u>342.6</u>	11.8	3.6%	330.0
Royalty and others	156.1	<u>173.2</u>	17.1	10.9%	160.0

<u>Goods and Products (Japan)</u>	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
OPDIVO Intravenous Infusion	120.3	<u>114.3</u>	-6.0	-5.0%	120.0
FORXIGA Tablets	89.6	<u>88.2</u>	-1.4	-1.5%	80.0
ORENCIA for Subcutaneous Injection	26.6	<u>26.6</u>	-0.0	-0.0%	28.0
GLACTIV Tablets	18.3	<u>13.2</u>	-5.1	-27.9%	12.0
VELEXBRU Tablets	10.5	<u>11.9</u>	1.4	12.8%	11.0
ONGENTYS Tablets	7.6	<u>9.0</u>	1.3	17.3%	9.0
PARSABIV Intravenous Injection	8.4	<u>9.0</u>	0.6	6.6%	9.0
KYPROLIS for Intravenous Infusion	8.6	<u>7.5</u>	-1.1	-12.9%	9.0
BRAFTOVI Capsules	4.2	<u>5.6</u>	1.4	33.8%	—

* The consolidated financial forecast for the fiscal year ended March 2026, announced on October 30, 2025, is provided.

• Sales revenue of domestic products is shown in a gross sales basis (shipment price), and sales revenue of overseas products is shown in a net sales basis.

FY2025 : Sales Revenue by Product / Overseas / Royalty



JPY bn	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
Revenue	486.9	<u>515.8</u>	28.9	5.9%	490.0
Goods and products	330.8	<u>342.6</u>	11.8	3.6%	330.0
Royalty and others	156.1	<u>173.2</u>	17.1	10.9%	160.0

Goods and Products (Overseas)	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
OPDIVO®	13.1	<u>14.2</u>	1.0	8.0%	13.5
QINLOCK®	25.5	<u>38.4</u>	12.9	50.6%	36.0
ROMVIMZA®	N/A	<u>8.3</u>	—	—	8.0

Royalty and others	FY2024	FY2025	YoY	
			Change	Change(%)
OPDIVO®	113.0	<u>122.3</u>	9.3	8.2%
KEYTRUDA®	26.4	<u>29.5</u>	3.0	11.4%

* The consolidated financial forecast for the fiscal year ended March 2026, announced on October 30, 2025, is provided.

• Sales revenue of domestic products is shown in a gross sales basis (shipment price), and sales revenue of overseas products is shown in a net sales basis.

FY2025 : Core Operating Profit



Core Operating Profit
137.1 JPY bn

YoY +24.5 JPY bn
(+21.7%)



Revenue 515.8 JPY bn

YoY +28.9 JPY bn (+5.9%)



R&D Expense 145.1 JPY bn

YoY +1.8 JPY bn (+1.2%)




SG&A Expense 123.6 JPY bn

YoY +1.4 JPY bn (+1.1%)

FY2025 : Core Operating Profit (Breakdown)

While R&D and SG&A expenses have been recorded by Deciphera (the previous period accounted for nine months, and the current period includes twelve months), core operating profit increased by 24.5 JPY bn year on year to 137.1 JPY bn mainly due to an increase in sales revenue and promotion of cost efficiency.



FY2025 : Financial Overview (Core)

JPY bn	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
Revenue	486.9	<u>515.8</u>	28.9	5.9%	490.0
Cost of sales	106.9	<u>107.0</u>	0.2	0.2%	103.5
R&D expenses	143.3	<u>145.1</u>	1.8	1.2%	150.0
SG&A expenses	122.2	<u>123.6</u>	1.4	1.1%	120.0
Core operating profit	112.7	<u>137.1</u>	24.5	21.7%	114.0
Core profit before tax	113.9	<u>138.3</u>	24.4	21.4%	114.0
Core profit for the year (attributable to owners of the Company)	90.4	<u>103.5</u>	13.1	14.5%	91.0

YoY Breakdown

Cost of sales +0.2 JPY bn (+0.2%)

COGS ratio : 20.8%

R&D expenses +1.8 JPY bn (+1.2%)

R&D ratio : 28.1%

Main reason

- Increase in R&D expenses from Deciphera (previous year : nine months, current year: twelve months)

SG&A expenses +1.4 JPY bn (+1.1%)

SG&A ratio : 24.0%

Main reason

- Increase in SG&A expenses from Deciphera (previous year : nine months, current year : twelve months)

Core operating profit ratio : 26.6%

* The consolidated financial forecast for the fiscal year ended March 2026, announced on October 30, 2025, is provided.

(Ref) FY2025 : Financial Overview (Full Basis)

JPY bn	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
Revenue	486.9	<u>515.8</u>	28.9	5.9%	490.0
Cost of sales	147.9	<u>141.7</u>	-6.2	-4.2%	135.0
R&D expenses	149.9	<u>147.0</u>	-2.8	-1.9%	150.0
SG&A expenses	125.7	<u>123.7</u>	-2.0	-1.6%	120.0
Operating profit	59.7	<u>92.2</u>	32.5	54.4%	85.0
Profit before tax	59.3	<u>92.7</u>	33.3	56.2%	85.0
Profit for the year (attributable to owners of the Company)	50.0	<u>69.8</u>	19.7	39.4%	67.0

YoY Breakdown

Cost of sales -6.2JPY bn (-4.2%)

COGS ratio : 27.5%

Main reason

- Absence of the sales milestone payment recorded in the previous fiscal year.

R&D expenses -2.8 JPY bn (-1.9%)

R&D ratio : 28.5%

Main reasons

- Increase in R&D expenses from Deciphera
- Absence of impairment loss related to development compounds recorded in the previous fiscal year

SG&A expenses -2.0 JPY bn (-1.6%)

SG&A ratio : 24.0%

Main reasons

- Increase in SG&A expenses from Deciphera
- Absence of expenses associated with the acquisition of Deciphera

Operating profit ratio : 17.9%

* The consolidated financial forecast for the fiscal year ended March 2026, announced on October 30, 2025, is provided.

(Ref) FY2025 : Reconciliation from Full to Core Basis

JPY bn	IFRS (Full) basis	Adjustment				Core basis
		Amortization	Impairment loss	Others	Total	
Revenue	515.8				—	515.8
Cost of sales	141.7	-25.6		-9.1	-34.7	107.0
Gross profit	374.1	+25.6	—	+9.1	+34.7	408.7
R&D expenses	147.0		-1.9		-1.9	145.1
SG&A expenses	123.7			-0.1	-0.1	123.6
Other income /expenses (- Exp)	-11.1		+0.2	+8.0	+8.2	-2.9
Operating profit	92.2	+25.6	+2.1	+17.2	+44.9	137.1
Operating profit ratio	17.9%				—	26.6%
Finance income / Finance cost (- Exp)	0.4			+0.7	+0.7	1.1
Profit before tax	92.7	+25.6	+2.1	+17.9	+45.6	138.3
Income tax expense	22.7	+6.5	+0.6	+4.8	+11.9	34.6
Profit for the year	69.8	+19.2	+1.5	+13.1	+33.7	103.5

Breakdown

Cost of sales

Main reasons

- Amortization expenses related to intangible assets acquired through acquisitions or in-licensing
- Amortization expenses related to inventories from *PPA

R&D expenses

Main reason

- Amortization expenses related to development compounds

SG&A expenses and Other income&expense


Main reasons

- Loss on retirement benefit plan amendments
- Loss on product recall related to OPDIVO
- Loss on the termination of the co-promotion agreement for FORXIGA Tablets

*PPA : Purchase Price Allocation


Balance sheet (Consolidated)

Structural transformation toward growth driven by proactive strategic investments



Capital Allocation (FY2022-2026)

■ Planned as of Apr 2022
 ■ Assumption for FY2025-2026
 ■ Result of FY2022-2024



FY2026 Financial Forecasts

FY2026 : Financial Forecast



Revenue
455.0 JPY bn

YoY -60.8 JPY bn
(-11.8%)



Goods and Products Sales
270.0 JPY bn

YoY -72.6 JPY bn (-21.2%)



Royalty and Others
185.0 JPY bn

YoY +11.8 JPY bn (+6.8%)

FY2026 : Financial Forecast (Sales by Product)

JPY bn


Goods and Products (Japan)	FY2025	FY2026 Forecast	YoY	
			Change	Change (%)
OPDIVO Intravenous Infusion	114.3	<u>120.0</u>	5.7	5.0%
ORENCIA for Subcutaneous Injection	26.6	<u>19.0</u>	-7.6	-28.6%
VELEXBRU Tablets	11.9	<u>12.0</u>	0.1	0.9%
PARSABIV Intravenous Injection	9.0	<u>10.0</u>	1.0	11.2%
ONGENTYS Tablets	9.0	<u>10.0</u>	1.0	11.5%
GLACTIV Tablets	13.2	<u>9.5</u>	-3.7	-28.1%
BRAFTOVI Capsules	5.6	<u>8.5</u>	2.9	51.5%
KYPROLIS for Intravenous Infusion	7.5	<u>7.0</u>	-0.5	-6.6%

Goods and Product (Overseas)	FY2025	FY2026 Forecast	YoY	
			Change	Change (%)
OPDIVO®	14.2	<u>13.0</u>	-1.2	-8.2%
QINLOCK®	38.4	<u>43.0</u>	4.6	12.1%
ROMVIMZA	8.3	<u>19.0</u>	10.7	129.4%

* Sales revenue of domestic products is shown in a gross sales basis (shipment price).

* Sales revenue of overseas products is shown in a net sales basis.

OPDIVO Sales Trend by Each Cancer




Progress Status of Key Indications (Apr. 2025 – Mar. 2026)

- GC : Progressed as per revised plan despite impact of competing products
- NSCLC : New prescription share in the PD-L1 negative segment is growing, but has not reached the plan; further activities are being strengthened to further expansion
- ESC : Although new competing products have entered the market, new prescription share increased and progress is on track
- HC / CRC : New prescription share remains steady

ROMVIMZA – Commercial Progress


Key Highlights

- ◆ Regulatory approvals obtained in the U.S. (FDA, February 2025) and Europe (EMA, September 2025)
- ◆ Market penetration progressing at a pace exceeding initial expectations
- ◆ In the TGCT market, a rare-disease area, increasing disease awareness and timely initiation of appropriate treatment are critical




ROMVIMZA Growth Opportunities in the TGCT Market

- ◆ In the TGCT market, a rare-disease area, increasing disease awareness and timely initiation of appropriate treatment are critical




Awareness-Building Initiatives in Orthopedics

Symposium





Website



Expansion and Acceleration of Global Business

Expand the share of global sales excluding Japan



FY2026 : Financial Forecast (Core Operating Profit)



Core Operating Profit
124.0 JPY bn

YoY -13.1 JPY bn
(-9.6%)



Revenue 455.0 JPY bn

YoY -60.8 JPY bn (-11.8%)



R&D Expense 143.0 JPY bn

YoY -2.1 JPY bn (-1.5%)



SG&A Expense 101.0 JPY bn

YoY -22.6 JPY bn (-18.3%)

(Ref) FY2026 : Financial Forecast (Core/Compared to the Previous Year)



JPY bn	FY2025 Actual	FY2026 Forecast	Change	Change (%)
Revenue	515.8	<u>455.0</u>	-60.8	-11.8%
Cost of sales	107.0	<u>84.0</u>	-23.0	-21.5%
R&D expenses	145.1	<u>143.0</u>	-2.1	-1.5%
SG&A expenses	123.6	<u>101.0</u>	-22.6	-18.3%
Core operating profit	137.1	<u>124.0</u>	-13.1	-9.6%
Core profit before tax	138.3	<u>124.0</u>	-14.3	-10.3%
Income tax expense	34.6	<u>31.0</u>	-3.6	-10.5%
Core profit for the year (attributable to owners of the Company)	103.5	<u>93.0</u>	-10.5	-10.1%

Breakdown

Cost of sales -23.0 JPY bn (-21.5%)

COGS ratio : 18.5%

Main reason

- Decrease in sales related to FORXIGA tablets due to the termination of the co-promotion agreement

R&D expenses -2.1 JPY bn (-1.5%)

R&D ratio: 31.4%

Main reasons

- A reclassification of certain expenses previously recorded as R&D expenses to SG&A expenses
- Increase in global clinical trial costs

SG&A expenses -22.6 JPY bn (-18.3%)

SG&A ratio : 22.2%

Main reason


- The termination of co-promotion agreement for FORXIGA Tablets

Core operating profit ratio : 27.3%

* The exchange rate assumed in the financial forecast is ¥155 per US dollar.

Core Operating Profit and Other Expense Trends

In FY2026, continue R&D investment, while anticipating reductions in SG&A expenses and cost of sales.



FY2026 : Financial Forecast (Full / Compared to the Previous Year)



JPY bn	FY2025 Actual	FY2026 Forecast	Change	Change (%)
Revenue	515.8	<u>455.0</u>	-60.8	-11.8%
Cost of sales	141.7	<u>114.0</u>	-27.7	-19.6%
R&D expenses	147.0	<u>143.0</u>	-4.0	-2.7%
SG&A expenses	123.7	<u>101.0</u>	-22.7	-18.3%
Operating profit	92.2	<u>94.0</u>	1.8	1.9%
Profit before tax	92.7	<u>94.0</u>	1.3	1.5%
Income tax expense	22.7	<u>23.0</u>	0.3	1.1%
Profit for the year (attributable to owners of the Company)	69.8	<u>71.0</u>	1.2	1.8%

Breakdown

Cost of sales -27.7 JPY bn (-19.6%)

COGS ratio : 25.1%

Main reason

- Decrease in sales related to FORXIGA tablets due to the termination of the co-promotion agreement

R&D expenses -4.0 JPY bn (-2.7%)

R&D ratio: 31.4%

Main reasons

- A reclassification of certain expenses previously recorded as R&D expenses to SG&A expenses
- Increase in global clinical trial costs

SG&A expenses -22.7 JPY bn (-18.3%)

SG&A ratio : 22.2%

Main reason

- The termination of co-promotion agreement for FORXIGA Tablets


Operating profit ratio : 20.7%

* The exchange rate assumed in the financial forecast is ¥155 per US dollar.

The sensitivity to exchange rates is assumed to be an increase of ¥1.5 billion in revenue and an increase of ¥0.5 billion in operating profit for every ¥1 depreciation of the yen.

Profit Distribution (Dividend)

Dividends are to be paid out in accordance with a progressive policy of maintaining or increasing the annual dividend each year, with a target payout ratio of 40%, taking into account the performance of each fiscal year and various indices.



Dividend payout ratio (consolidated)

34.5%

30.3%

30.0%

75.1%


53.9%

52.9%

Key Development Pipeline Milestones

As of May 8, 2026

- Initiation of three global Phase 3 and data readouts from seven POC studies in FY2026
- In the priority areas of oncology, immunology & inflammation, and neurology, four new pipelines have initiated phase 1 study.



Tirabrutinib Development Status in the United States

Tirabrutinib is an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor that is currently under review by the U.S. FDA for the treatment of relapsed or refractory primary central nervous system lymphoma (R/R PCNSL).


- Positive results from Phase 2 PROSPECT study demonstrated overall response rate of 67%, complete response rate of 44%
- PDUFA date set for 12/18/2026
- Preparing for U.S. commercialization
- Recruiting patients for Global Phase 3 confirmatory study



Source: PCNSL Disease Awareness Website
<https://www.navigatingpcnsl.com/>

Prospect for the Future

Growth Drivers



Pipeline	Peak Sales (JPY bn)
Global	
QINLOCK (GIST)	50 – 70
ROMVIMZA (TGCT)	50 – 70
Tirabrutinib (PCNSL)	20 – 30
Sapablursen (PV)	50 – 100
ONO-4578 (GC)	100 -
ONO-2808 (MSA)	100 -
Japan*	
Povetacicept	50 -
Cenobamate	
Gel-One®	

*Total estimated peak sales, including products other than the three listed.

Japan Sales

※Diagram does not represent actual sales of each product

As of May 8, 2026